Coagulase-negative staphylococci (CoNS), particularly *Staphylococcus epidermidis*, belong to the microbiota of human skin and the mucosal membrane of the upper respiratory tract, and they express low pathogenic potential as commensals in healthy people ([@B32], [@B22]. However, they can be responsible for several serious infections in immunocompromised patients, particularly those associated with biomaterials (e.g., catheters, prosthetics etc.), leading to bacteraemia and sepsis ([@B35],[@B7], [@B27], [@B8]). On the other hand, as a natural part of the microflora, drug resistant strains may be selected during antibiotic therapy, which is a potential source of the resistance genes for pathogenic strains, e.g.,*Staphylococcus aureus* ([@B24], [@B23], [@B31]).

Resistance to macrolide, lincosamide, and streptogramins B (MLS~B~ antibiotics) in staphylococci is associated with the following three mechanisms: (i) target modification, (ii) efflux pumps, and (iii) enzymatic modification of antibiotics. The first macrolide-resistant staphylococcal strains were identified in the 1950s ([@B26]). Currently, a large number of strains exhibit resistance to these antibiotics *via* different mechanisms. It is known that macrolide-resistant strains often exhibit co-resistance to other MLS~B~ antibiotics. The most common mechanism is the modification of ribosomes as a result of methylation of adenine within 23S rRNA ribosomal subunits by a methylase encoded by the *erm* genes (predominantly*ermC*). Conformational changes in the ribosome result in the reduced binding of all MLS~B~ antibiotics; these strains are resistant to all MLS~B~ antibiotics (the combination of quinupristin/dalfopristin loses bactericidal activity as the result of the development of resistance to quinupristin). The phenotypic expression of MLS~B~ resistance can be either inducible (iMLS~B~) (generally induced by 14 and 15-membered macrolides) or constitutive (cMLS~B~) ([@B34]). The active efflux of antibiotics is mediated by *msr* genes (mainly*msrA*) and is responsible for resistance only to 14 and 15-membered macrolides and streptogramins B (MS~B~) phenotype ([@B25]). The third mechanism of resistance is based on the production of antibiotic-inactivating enzymes (e. g., phosphorylase encoded by*mph* or *lin*, the gene responsible for inactivation of lincosamides) ([@B10], [@B1]).

The aim of this study was to assess the prevalence of different MLS~B~resistance phenotypes among *S. epidermidis*, together with the evaluation of genes responsible for target modification (*ermA*,*ermB*, *ermC*), antibiotic efflux (*msrA*) or antibiotic inactivation (*mphC*,*linA/A'*). The evaluation of susceptibility to the 16-membered macrolide spiramycin was also performed.

This paper was developed using the equipment purchased within agreement POPW.01.03.00-06-010/09-00 Operational Program Development of Eastern Poland 2007-2013, Priority Axis I, Modern Economy, Operations 1.3. Innovations Promotion.

SUBJECTS, MATERIALS AND METHODS
===============================

*Bacterial strains* - A total of 197 strains of *S. epidermidis* were obtained from the mucosal membranes of the upper respiratory tracts of patients with nonsmall cell lung cancer who underwent hospitalisation. Nasal and pharyngeal swabs were obtained on the second day of the patients' stays at the hospital. Among the strains, resistance to erythromycin was detected in 75 isolates.

*Isolation and identification* - Isolation and identification of bacterial strains were performed using routine microbiological tests. The following tests were used in the identification of CoNS: the coagulase test tube using rabbit plasma (Biomed, Poland) and API Staph strips (bioMérieux, France).

*Identification of resistance to MLS* ~*B*~ *antibiotics* - Susceptibility to MLS~B~ antibiotics, including the detection of resistance mechanisms, was based on the D-test according to European Centre for Disease Prevention and Control (EUCAST) recommendations. In addition, disks containing lincomycin (15 mg) were used to identify the L-phenotype. Moreover, for detection of the effects of spiramycin on clindamycin susceptibility, discs containing spiramycin (100 mg) were applied next to clindamycin (2 mg).

*Determination of minimal inhibitory concentrations (MICs) to spiramycin* - Detection of MICs to spiramycin was based on EUCAST recommendations using the double broth dilution method. In the absence of breakpoints for spiramycin in EUCAST, only the MICs were evaluated without grouping the strains as susceptible or resistant.

*Isolation of bacterial DNA* - The DNA Genomic Mini Kit (A&A Biotechnology, Poland) was used to isolate *S. epidermidis* DNA according to the manufacturer's guidelines.

*Identification of genes by polymerase chain reaction (PCR)* - The sequences of the primers and the conditions of the PCR reactions are presented in[Table I](#t1){ref-type="table"}. For the PCR reactions, PCR REDTaq^®^ Ready Mix^TM^ PCR Mix with MgCl~2~(Sigma-Aldrich, USA) was used. The final volume of each PCR reaction was 25 ml and contained 12.5 ml of REDTaq Ready Mix, 1 ml of each forward and reverse primer (concentration between 0.1-1.0 mM), 1 ml of DNA (50-200 ng), and 9 ml of water. The reactions were performed using a Whatman Biometra thermocycler, whereas the PCR products were subjected to agarose gel electrophoresis (2% agarose, 1xTRIS-acetate-EDTA, 120 mV, 40 min). The gels were stained with ethidium bromide and the PCR products were visualised using a Wilbert Lambert transilluminator and compared with molecular size markers \[Gene Ruler^TM^ 100 bp DNA Ladder (Fermentas, Thermo Scientific, USA)\].

TABLE IPrimers sequence, thermal cycling profile, and size of amplified polymerase chain reaction (PCR) fragment in each PCR reaction in the detection of genes of *Staphylococcus epidermidis*resistant to erythromycin*a*GenePrimers sequencePCR conditionsPCR fragment size (bp)*ermA*5'-TCTAAAAAGCATGTAAAAGAA-3' 5'-CTTCGATAGTTTATTAATATTAGT-3'35 (30 s at 94ºC, 1 min at 48ºC, 2 min at 72ºC)645*ermB*5'-GAAAAGGTACTCAACCAAATA-3' 5'-AGTAACGGTACTTAAATTGTTTAC-3'35 (30 s at 94ºC, 30 s at 50ºC, 2 min at 72ºC)639*ermC*5'-AGTACAGAGGTGTAATTTCG-3' 5'-AATTCCTGCATGTTTTAAGG-3'35 (55 s at 94ºC, 1 min at 53ºC, 1 min at 72ºC)642*msrA*5'-GGCACAATAAGAGTGTTTAAAGG-3' 5'-AAGTTATATCATGAATAGATTGTCCTGTT-3'25 (1 min at 94ºC, 1 min at 50ºC, 90 s at 72ºC)399*mphC*5'-GAGACTACCAGACCTGACG-3' 5'-CATACGCCGATTCTCCTGAT-3'35 (1 min at 94ºC, 1 min at 59ºC, 1 min at 72ºC)530*linA/A'*5'-GGTGGCTGGGGGGTAGATGTATTAACTGG-3' 5'-GCTTCTTTTGAAATACATGGTATTTTTCGATC-3'30 (30 s at 94ºC, 30 s at 57ºC, 1 min at 72ºC)323[^1]

*Ethics* - The study design and protocols were approved by the Ethical Committee of the Medical University of Lublin (KE-0254/75/2011).

RESULTS
=======

The 75 *S. epidermidis* isolates expressed resistance to erythromycin with the following mechanisms of resistance: 27 (36%) strains exhibited cMLS~B~ resistance, 14 (18.7%) strains exhibited iMLS~B~resistance, and 34 (45.3%) strains exhibited MS~B~ resistance ([Figure](#f01){ref-type="fig"}). Twenty-five isolates exhibited L-phenotypes and were determined to be either resistant to only lincomycin (24 strains) or resistant to lincomycin and clindamycin (1 strain).

The prevalence of different mechanisms of resistance to macrolide, lincosamide, and streptogramins B (MLSB) antibiotics among erythromycin-resistant *Staphylococcus epidermidis*. cMLSB: constitutive resistance to MLSB antibiotics; iMLSB: inducible resistance to MLSB antibiotics; MSB: resistance of MSB type.

The MICs of spiramycin among erythromycin-resistant *S. epidermidis*were evaluated as follows: \> 128 mg/L for all cMLS~B~ strains, from 4-\> 128 mg/L for iMLS~B~ strains, and from 1-4 mg/L for strains exhibiting the MS~B~ phenotype. The MIC~50~ and MIC~90~values were also calculated. Strains with cMLS~B~ and iMLS~B~phenotypes exhibited MIC~50~ and MIC~90~ values \> 128 mg/L, whereas the MIC~50~ and MIC~90~ values for the MS~B~strains were determined to 4 mg/L ([Table II](#t2){ref-type="table"}). Moreover, for the 11 (78.6%) strains exhibiting iMLS~B~ phenotypes, the noninhibition zone around the spiramycin disc was found together with a D-shaped zone around the clindamycin disk.

TABLE IIThe minimal inhibitory concentrations (MICs) to spiramycin among erythromycin-resistant *Staphylococcus epidermidis*mg/LiMLS~B~cMLS~B~MS~B~MIC range4-\> 128\> 1281-4MIC~50~\> 128\> 1284MIC~90~\> 128\> 1284[^2]

As shown in [Table III](#t3){ref-type="table"}, among the strains with cMLS~B~ resistance, the predominant genes were *ermC*and *mphC* in 23 (85.2%) and 24 (88.9%) strains, respectively.*linA/A*' was found to occur in 14 (51.8%) strains. The presence of other genes (e.g., *ermA* and *ermB*) was detected in a few strains; two strains did not possess any of the *erm* genes. The isolates with iMLS~B~ possessed the following genes:*ermC* - 14 (100%) strains, *msrA* - 7 (50%) strains, *mphC* - 13 (92.9%) strains, and *linA/A'* - 10 (71.4%) strains; *ermA* and *ermB* were not detected. The strains exhibiting MS~B~ resistance were found to possess the following genes: *ermC* in 20 (58.8%) strains, *msrA*in 32 (94.1%) strains, *mphC* in 33 (97.1%) strains, and*linA/A'* in 24 (70.6%) strains; these strains did not carry*ermA* or *ermB*. The strains exhibiting L-phenotypes contained *linA/A'* in 24 (96%) strains,*mphC* in 23 (92%) strains, and *ermC* in 24 (96%) strains. *ermA*, *ermB*, and *msrA*were not detected in the isolates with L-phenotypes. One strain did not carry any of the evaluated genes.

TABLE IIIThe prevalence of genes responsible for resistance to macrolide, lincosamide, and streptogramins B (MLSB) antibiotics among erythromycin-resistant *Staphylococcus epidermidis*GenePhenotypes n (%)cMLS~B~ (n = 27)iMLS~B~ (n = 14)MS~B~ (n = 34)L-phenotype (n = 25)*ermA*4 (14.8)0 (0)0 (0)0 (0)*ermB*1 (3.7)0 (0)0 (0)0 (0)*ermC*23 (85.2)14 (100)20 (58.8)24 (96)*msrA*5 (18.5)7 (50)32 (94.1)0 (0)*mphC*24 (88.9)13 (92.9)33 (97.1)23 (92)*linA/A'*14 (51.8)10 (71.4)24 (70.6)24 (96)[^3]

[Table IV](#t4){ref-type="table"} shows the combination of genes responsible for resistance to MLS~B~ antibiotics among staphylococci. In isolates exhibiting cMLS~B~ resistance, 11 different combinations were detected. The most frequent gene combination was *ermC*,*mphC*, and *linA/A'*, which was found in 10 (37%) strains. Among the strains exhibiting iMLS~B~ resistance, four gene combinations were evaluated. The most frequent combinations contained the following genes: *ermC*, *mphC*, and *linA/A'* in five (35.7%) isolates and *ermC*, *msrA*,*mphC*, and *linA/A'*, also in five (35.7%) isolates. The MS~B~-positive strains contained six different gene combinations in three major groups: *ermC*, *msrA*,*mphC*, and *linA/A'* in 14 (41.2%) strains;*msrA*, *mphC*, and *linA/A'* in nine (26.5%) strains, and *ermC*, *msrA*, and*mphC* in six (17.6%) strains. In the isolates with L-phenotypes, the most significant three-gene combination was *ermC*,*mphC*, and *linA/A'* in 21 (84%) strains.

TABLE IVThe prevalence of gene combinations responsible for resistance to macrolide, lincosamide, and streptogramins B (MLSB) antibiotics among erythromycin-resistant *Staphylococcus epidermidis*Gene combinationsPhenotypes n (%)cMLS~B~ (n = 27)iMLS~B~ (n = 14)MS~B~ (n = 34)L-phenotype (n = 25)*ermC*1 (3.7)1 (7.1)0 (0)0 (0)*mphC*0 (0)0 (0)2 (5.9)0 (0)*ermC*, *mphC*4 (14.8)3 (21.4)0 (0)0 (0)*ermB*, *mphC*1 (3.7)0 (0)0 (0)0 (0)*ermC*, *linA/A'*1 (3.7)0 (0)0 (0)2 (8)*ermA*, *mphC*1 (3.7)0 (0)0 (0)0 (0)*msrA*, *mphC*0 (0)0 (0)2 (5.9)0 (0)*msrA*, *linA/A'*0 (0)0 (0)1 (2.9)0 (0)*mphC*, *linA/A'*0 (0)0 (0)0 (0)1 (4)*ermC*, *msrA*,*mphC*3 (11.1)0 (0)6 (17.6)0 (0)*ermC*, *mphC*,*linA/A'*10 (37)5 (35.7)0 (0)21 (84)*msrA*, *mphC*,*linA/A'*1 (3.7)0 (0)9 (26.5)0 (0)*ermA*, *ermC*,*mphC*2 (7.4)0 (0)0 (0)0 (0)*ermC*, *msrA*,*mphC*, *linA/A'*1 (3.7)5 (35.7)14 (41.2)0 (0)*ermA*, *ermC*,*mphC*, *linA/A'*1 (3.7)0 (0)0 (0)0 (0)Without genes1 (3.7)0 (0)0 (0)1 (4)[^4]

DISCUSSION
==========

CoNS are potential reservoirs of antibiotic resistance genes, which can be transferred to *S. aureus* not only in vitro but also in vivo ([@B24], [@B23]). Erythromycin resistance among CoNS was previously reported to result from a methylase encoded by different *erm* family genes that can be horizontally transferred to recipient strains ([@B36], [@B31]). Hence, surveillance of erythromycin resistance and MLS~B~ resistance in CoNS at phenotypic and genetic levels can provide important information regarding their current epidemiology.

Among the *S. epidermidis* strains studied, the most frequently identified gene in strains exhibiting both cMLS~B~ and iMLS~B~phenotypes was *ermC*, which is consistent with previous reports ([@B24], [@B13], [@B11], [@B4],[@B5], [@B14]). Only a few *S. epidermidis* exhibiting cMLS~B~ phenotypes possessed*ermA* and/or *ermB.* Similar data have been previously reported ([@B4],[@B30], [@B29]). Moreover, the presence of other *erm* genes (e.g., *ermF)* has been rarely detected in *Staphylococcus* spp ([@B26]. Notably, the distribution of *erm* genes depends on the bacterial species. For example, *ermA* is more characteristic of *S. aureus,* whereas *ermB* is more characteristic of beta-haemolytic streptococci ([@B26], [@B6],[@B18], [@B31]). Moreover, among CoNS, the type of*erm* gene also depends on the geographical region of their isolation. For example, *ermC* was previously detected in 50% of the strains exhibiting MLS~B~ resistance in Great Britain, whereas it was detected 90% of those in Denmark ([@B16], [@B12], [@B9], [@B4]) and in Mexico, *ermA* was reported as predominant in *S. epidermidis* ([@B8]).

The MS~B~ *S. epidermidis* isolates examined contained an*msrA* gene encoding an ATP-dependent efflux pump, which actively removes 14-,15-membered MS~B~. The MS~B~ phenotype observed in*msrA*-negative *S. epidermidis* strains may be the result of the presence of *mphC*, which encodes for a macrolide-modifying enzyme ([@B12]), thereby resulting in a "false-positive" MS~B~phenotype.

All *S. epidermidis* isolates with L-phenotypes generally contained the *linA/A'* gene. Data from [@B19], [@B21]) also indicated a connection between the presence of the *linA/A'* gene and resistance to only lincomycin among staphylococci. The *S. epidermidis* strains studied exhibited resistance to lincomycin, but susceptibility to clindamycin as a result of increased enzyme affinity for lincomycin ([@B2]). Resistance both to lincomycin and clindamycin may be a consequence of the presence of other*lin* family genes or*vga(A)* ~*LC*~, which encodes a "new" variant of the SgA protein that is responsible for cross-resistance to streptogramins A and all lincosamides ([@B20]).

Among the iMLS~B~ and cMLS~B~ *S. epidermidis*strains, the *erm* genes do not exist separately, but in combination with others (predominantly with *mphC*). Notably, other*erm* genes (e.g., *ermF*), which are rarely detected in *Sta- phylococcus* spp, may encode both the inducible or constitutive MLS~B~ phenotypes ([@B26]). In MS~B~-positive *S. epidermidis*strains, the *msrA* genes predominantly coexist with*ermC*, *mphC*, and *linA/A'*, and the coexistence of *msrA* and *ermC* has also been previously reported ([@B26], [@B21], [@B33], [@B30]). Moreover, the presence of the *linA/A'* gene in*msrA*-positive strains results in resistance to lincomycin. The*S. epidermidis* strains exhibiting L-phenotypes correlated with the presence of the *linA/A'* gene in most of the strains that also contained the *ermC* and *mphC* genes, whereas those strains did not contain the *msrA* gene. Notably, the*ermC* genes were also detected in both of the MS~B~ and L-phenotype *S. epidermidis* strains - but without its expression - suggesting a defect in *ermC* expression.

Previous studies have reported ([@B15],[@B11]) that 16-membered macrolides (e.g., spiramycin) are not inducers of MLS~B~ resistance in staphylococci. According to our data, spiramycin is able to induce resistance to clindamycin among the iMLS~B~ *S. epidermidis* isolates examined. Moreover, iMLS~B~ *S. epidermidis* strains, which contain *ermC*, exhibited resistance to spiramycin in vitro. These observations contradict previous reports that 16-membered macrolides remain active against staphylococci that exhibit iMLS~B~ phenotypes ([@B15], [@B29]). Notably, resistance to spiramycin appears to be characteristic of iMLS~B~ streptococci containing *ermB*([@B15], [@B3]).

The diversity of genes involved in different mechanisms that are responsible for the resistance of *S. epidermidis* to MLS~B~ antibiotics suggests that the insensitivity of CoNS strains to these antibacterial drugs is not necessarily a unidirectional process and that the coexistence of various genes may influence the nature of their resistance.

[^1]: *a*: Sutcliffe et al. (1996) and Lina et al. (1999).

[^2]: cMLS~B~: constitutive resistance to macrolide, lincosamide, and streptogramins B (MLS~B~) antibiotics; iMLS~B~: inducible resistance to MLS~B~antibiotics; MS~B~: resistance of MS~B~ type.

[^3]: cMLS~B~: constitutive resistance to MLS~B~antibiotics; iMLS~B~: inducible resistance to MLS~B~ antibiotics; MS~B~: resistance of MS~B~ type.

[^4]: cMLS~B~: constitutive resistance to MLS~B~antibiotics; iMLS~B~: inducible resistance to MLS~B~ antibiotics; MS~B~: resistance of MS~B~ type.
